[Gilles de la Tourette's disease].
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D003937:Diagnosis, Differential; D003951:Diagnostic Errors; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D010275:Parasympathetic Nervous System / Q000503:physiopathology; D010640:Phenothiazines / Q000627:therapeutic use; D011602:Psychophysiologic Disorders / Q000175:diagnosis; D011954:Receptors, Dopamine / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000503:physiopathology; D005879:Tourette Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000978:Antiparkinson Agents; D010640:Phenothiazines; D011954:Receptors, Dopamine; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D006220:Haloperidol
La maladie de Gilles de la Tourette